10,325 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,325 shares of the company’s stock, valued at approximately $81,000.

Other large investors also recently bought and sold shares of the company. Franklin Resources Inc. increased its holdings in Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after acquiring an additional 4,178 shares in the last quarter. Gladius Capital Management LP purchased a new stake in Amneal Pharmaceuticals during the 3rd quarter worth about $37,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Amneal Pharmaceuticals by 13.6% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock valued at $366,000 after purchasing an additional 5,523 shares during the last quarter. Segall Bryant & Hamill LLC boosted its stake in shares of Amneal Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 489,162 shares of the company’s stock worth $4,070,000 after purchasing an additional 7,661 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $84,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRX has been the subject of several recent analyst reports. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Amneal Pharmaceuticals Stock Down 2.3 %

Shares of AMRX stock opened at $7.73 on Friday. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.48. The firm’s 50 day moving average price is $8.07 and its two-hundred day moving average price is $8.25. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -11.37 and a beta of 1.10.

Insider Activity at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the sale, the director now directly owns 1,888,886 shares in the company, valued at approximately $15,375,532.04. This represents a 4.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 160,000 shares of company stock worth $1,292,000. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.